- Home
- TORO vs KZIA Comparison
TORO vs KZIA Comparison
Compare TORO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TORO | KZIA |
|---|---|---|
| Founded | 2022 | 1994 |
| Country | Cyprus | Australia |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.5M | 154.5M |
| IPO Year | 2022 | 2002 |
Fundamental Metrics
Financial Performance| Metric | TORO | KZIA |
|---|---|---|
| Price | $6.10 | $13.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 22.4K | ★ 207.4K |
| Earning Date | 04-15-2026 | 06-04-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.64 | $4.86 |
| 52 Week High | $8.50 | $17.40 |
Technical Indicators
Market Signals| Indicator | TORO | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 72.65 | 52.57 |
| Support Level | $4.87 | $11.39 |
| Resistance Level | $8.50 | $14.75 |
| Average True Range (ATR) | 0.38 | 1.02 |
| MACD | 0.05 | 0.12 |
| Stochastic Oscillator | 74.02 | 59.56 |
Price Performance
Historical ComparisonAbout TORO Toro Corp.
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.